1. Home
  2. ABUS vs VSTS Comparison

ABUS vs VSTS Comparison

Compare ABUS & VSTS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ABUS
  • VSTS
  • Stock Information
  • Founded
  • ABUS 2005
  • VSTS 1936
  • Country
  • ABUS United States
  • VSTS United States
  • Employees
  • ABUS N/A
  • VSTS N/A
  • Industry
  • ABUS Biotechnology: Pharmaceutical Preparations
  • VSTS
  • Sector
  • ABUS Health Care
  • VSTS
  • Exchange
  • ABUS Nasdaq
  • VSTS Nasdaq
  • Market Cap
  • ABUS 711.2M
  • VSTS 572.2M
  • IPO Year
  • ABUS N/A
  • VSTS N/A
  • Fundamental
  • Price
  • ABUS $4.38
  • VSTS $5.06
  • Analyst Decision
  • ABUS Strong Buy
  • VSTS Sell
  • Analyst Count
  • ABUS 2
  • VSTS 4
  • Target Price
  • ABUS $5.00
  • VSTS $9.13
  • AVG Volume (30 Days)
  • ABUS 1.4M
  • VSTS 2.3M
  • Earning Date
  • ABUS 11-05-2025
  • VSTS 11-20-2025
  • Dividend Yield
  • ABUS N/A
  • VSTS 1.39%
  • EPS Growth
  • ABUS N/A
  • VSTS N/A
  • EPS
  • ABUS N/A
  • VSTS N/A
  • Revenue
  • ABUS $15,416,000.00
  • VSTS $2,707,109,000.00
  • Revenue This Year
  • ABUS $138.02
  • VSTS N/A
  • Revenue Next Year
  • ABUS N/A
  • VSTS $0.25
  • P/E Ratio
  • ABUS N/A
  • VSTS N/A
  • Revenue Growth
  • ABUS 53.23
  • VSTS N/A
  • 52 Week Low
  • ABUS $2.71
  • VSTS $3.98
  • 52 Week High
  • ABUS $5.10
  • VSTS $17.83
  • Technical
  • Relative Strength Index (RSI)
  • ABUS 54.52
  • VSTS 65.92
  • Support Level
  • ABUS $4.25
  • VSTS $4.02
  • Resistance Level
  • ABUS $4.66
  • VSTS $4.24
  • Average True Range (ATR)
  • ABUS 0.17
  • VSTS 0.21
  • MACD
  • ABUS -0.03
  • VSTS 0.14
  • Stochastic Oscillator
  • ABUS 41.67
  • VSTS 95.40

About ABUS Arbutus Biopharma Corporation

Arbutus Biopharma Corp is a clinical-stage biopharmaceutical company focused on infectious diseases. The company is leveraging its extensive virology expertise to identify and develop novel therapeutics with distinct mechanisms of action, which can be combined to provide a functional cure for patients with chronic hepatitis B virus (cHBV). Its pipeline of internally developed, proprietary compounds includes an RNAi therapeutic, imdusiran (AB-729), and an oral PD-L1 inhibitor, AB-101. In addition, the company is also focused on maximizing the opportunity for its in-house developed Lipid Nanoparticle (LNP) delivery technology.

About VSTS Vestis Corporation

Vestis Corp is a provider of uniform rentals and workplace supplies across the United States and Canada. It provides uniforms, mats, towels, linens, restroom supplies, first-aid supplies, safety products, and other workplace supplies. The Company serves customers ranging from small, family-owned operations with a single location to large corporations and national franchises with multiple locations. The company operates in the United States and Canada as reportable segments. The company earns the majority of its revenue from the United States.

Share on Social Networks: